Total submissions: 6
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Counsyl | RCV000668716 | SCV000793361 | likely pathogenic | Ataxia-telangiectasia syndrome | 2017-08-15 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV001021947 | SCV001183627 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-10-29 | criteria provided, single submitter | clinical testing | The p.S1383* pathogenic mutation (also known as c.4148C>A), located in coding exon 27 of the ATM gene, results from a C to A substitution at nucleotide position 4148. This changes the amino acid from a serine to a stop codon within coding exon 27. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
| Labcorp Genetics |
RCV000668716 | SCV001592887 | pathogenic | Ataxia-telangiectasia syndrome | 2023-12-18 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Ser1383*) in the ATM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with ATM-related conditions. ClinVar contains an entry for this variant (Variation ID: 553301). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
| Myriad Genetics, |
RCV004026103 | SCV004932332 | pathogenic | Familial cancer of breast | 2024-01-23 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. |
| Baylor Genetics | RCV004026103 | SCV005056891 | likely pathogenic | Familial cancer of breast | 2024-03-11 | criteria provided, single submitter | clinical testing | |
| Center for Genomic Medicine, |
RCV004596324 | SCV005090314 | likely pathogenic | not provided | 2024-07-31 | criteria provided, single submitter | clinical testing |